Preclinical studies of IT-901, a novel and selective NF-κB inhibitor, revealed that it significantly reduced the tumor burden in a xenograft model that was implanted with chronic lymphocytic leukemia patient-derived cells [45]. This evidence concerns the gene NFKB1 and neoplasm.